A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours
Conclusion The daily oral dosing of BMS-986115 is safe and tolerable with biological activity demonstrated by continuous target engagement and Notch signalling inhibition.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Diarrhoea | Drugs & Pharmacology | Genetics | Hives | Investigational New Drugs | Oral Cancer | Stem Cell Therapy | Stem Cells | Study | Toxicology